AbbVie Inc. (ABBV) operating KPIs
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$294.89+4.10 (+1.41%)
Close on Oct 30, 2026Market cap $521.11BP/E 83.3Yield 2.26%
AbbVie research and Development (R&D) Expense — GAAP ($M) ($M)
Form 10-Q / 10-K Consolidated Statements of Earnings
Latest, Q2 2026
2,344
Period ended Jun 30, 2026
Change on a year earlier
+10.0%
2,131 in Q2 2025
History
46 quarters
Since Q1 2015
Sources
37
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Research and Development (R&D) Expense — GAAP ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 2,344 | +10.0% | Form 10-Q (filed 2026-08-03) ↗ |
| Q1 2026 | Mar 31, 2026 | 2,472 | +19.6% | Form 10-Q (filed 2026-05-08) ↗ |
| Q4 2025 | Dec 31, 2025 | 2,579 | -61.9% | Form 10-K (filed 2026-02-20) ↗ |
| Q3 2025 | Sep 30, 2025 | 2,319 | +8.9% | Form 10-Q (filed 2025-11-04) ↗ |
| Q2 2025 | Jun 30, 2025 | 2,131 | +9.4% | Form 10-Q (filed 2026-08-03) ↗ |
| Q1 2025 | Mar 31, 2025 | 2,067 | +6.6% | Form 10-Q (filed 2026-05-08) ↗ |
| Q4 2024 | Dec 31, 2024 | 6,774 | +251.5% | Form 10-K (filed 2026-02-20) ↗ |
| Q3 2024 | Sep 30, 2024 | 2,130 | +23.6% | Form 10-Q (filed 2025-11-04) ↗ |
| Q2 2024 | Jun 30, 2024 | 1,948 | +12.4% | Form 10-Q (filed 2025-08-04) ↗ |
| Q1 2024 | Mar 31, 2024 | 1,939 | -15.4% | Form 10-Q (filed 2025-05-09) ↗ |
| Q4 2023 | Dec 31, 2023 | 1,927 | +7.7% | Form 10-K (filed 2026-02-20) ↗ |
| Q3 2023 | Sep 30, 2023 | 1,723 | +6.8% | Form 10-Q (filed 2024-11-04) ↗ |
| Q2 2023 | Jun 30, 2023 | 1,733 | +7.7% | Form 10-Q (filed 2024-08-07) ↗ |
| Q1 2023 | Mar 31, 2023 | 2,292 | +53.1% | Form 10-Q (filed 2024-05-03) ↗ |
| Q4 2022 | Dec 31, 2022 | 1,790 | -2.0% | Form 10-K (filed 2025-02-14) ↗ |
| Q3 2022 | Sep 30, 2022 | 1,614 | -2.8% | Form 10-Q (filed 2023-11-06) ↗ |
| Q2 2022 | Jun 30, 2022 | 1,609 | -8.9% | Form 10-Q (filed 2023-08-07) ↗ |
| Q1 2022 | Mar 31, 2022 | 1,497 | -10.2% | Form 10-Q (filed 2023-05-05) ↗ |
| Q4 2021 | Dec 31, 2021 | 1,827 | +6.7% | Form 10-K (filed 2024-02-20) ↗ |
| Q3 2021 | Sep 30, 2021 | 1,661 | -2.6% | Form 10-Q (filed 2022-11-04) ↗ |
| Q2 2021 | Jun 30, 2021 | 1,767 | +11.7% | Form 10-Q (filed 2022-08-04) ↗ |
| Q1 2021 | Mar 31, 2021 | 1,667 | +20.9% | Form 10-Q (filed 2022-05-06) ↗ |
| Q4 2020 | Dec 31, 2020 | 1,712 | +11.0% | Form 10-K (filed 2023-02-17) ↗ |
| Q3 2020 | Sep 30, 2020 | 1,706 | -25.3% | Form 10-Q (filed 2021-11-02) ↗ |
| Q2 2020 | Jun 30, 2020 | 1,582 | +22.5% | Form 10-Q (filed 2021-08-02) ↗ |
| Q1 2020 | Mar 31, 2020 | 1,379 | +7.0% | Form 10-Q (filed 2021-05-07) ↗ |
| Q4 2019 | Dec 31, 2019 | 1,542 | -76.3% | Form 10-K (filed 2022-02-18) ↗ |
| Q3 2019 | Sep 30, 2019 | 2,285 | +80.2% | Form 10-Q (filed 2020-11-04) ↗ |
| Q2 2019 | Jun 30, 2019 | 1,291 | -2.3% | Form 10-Q (filed 2020-08-04) ↗ |
| Q1 2019 | Mar 31, 2019 | 1,289 | +3.6% | Form 10-Q (filed 2020-05-08) ↗ |
| Q4 2018 | Dec 31, 2018 | 6,495 | +361.3% | Form 10-K (filed 2021-02-19) ↗ |
| Q3 2018 | Sep 30, 2018 | 1,268 | +3.3% | Form 10-Q (filed 2019-11-06) ↗ |
| Q2 2018 | Jun 30, 2018 | 1,322 | +7.6% | Form 10-Q (filed 2019-08-05) ↗ |
| Q1 2018 | Mar 31, 2018 | 1,244 | +8.9% | Form 10-Q (filed 2019-05-03) ↗ |
| Q4 2017 | Dec 31, 2017 | 1,408 | +16.5% | Form 10-K (filed 2020-02-21) ↗ |
| Q3 2017 | Sep 30, 2017 | 1,228 | +11.0% | Form 10-Q (filed 2018-11-07) ↗ |
| Q2 2017 | Jun 30, 2017 | 1,229 | +9.3% | Form 10-Q (filed 2018-08-07) ↗ |
| Q1 2017 | Mar 31, 2017 | 1,142 | +20.7% | Form 10-Q (filed 2018-05-04) ↗ |
| Q4 2016 | Dec 31, 2016 | 1,209 | +12.5% | Form 10-K (filed 2019-02-27) ↗ |
| Q3 2016 | Sep 30, 2016 | 1,106 | -22.0% | 10-Q FY2016 (XBRL) ↗ |
| Q2 2016 | Jun 30, 2016 | 1,124 | +14.6% | 10-Q FY2016 (XBRL) ↗ |
| Q1 2016 | Mar 31, 2016 | 946 | +16.6% | 10-Q FY2016 (XBRL) ↗ |
| Q4 2015 | Dec 31, 2015 | 1,075 | – | Form 10-K (filed 2018-02-16) ↗ |
| Q3 2015 | Sep 30, 2015 | 1,418 | – | 10-Q FY2015 (XBRL) ↗ |
| Q2 2015 | Jun 30, 2015 | 981 | – | 10-Q FY2015 (XBRL) ↗ |
| Q1 2015 | Mar 31, 2015 | 811 | – | 10-Q FY2015 (XBRL) ↗ |
Breakdown
What makes up research and development (r&d) expense — gaap ($m)
- Adjusted R&D Expense — Non-GAAP ($M)2,314 · Q2 2026
- Adjusted Investment in R&D — ESG Report ($B)–
- GAAP R&D Expense % of Net Revenues (%)13.8% · Q2 2026
- Adjusted R&D Expense % of Net Revenues — Non-GAAP (%)13.6% · Q2 2026
- New Product or Indication Approvals (approvals)–
- Programs Granted Expedited Regulatory Designations (programs)–
- FDA Breakthrough Therapy Designations (designations)–
- Compounds in Late-Stage Clinical Development with Novel Mechanism of Action (%)–
Cite this data
StockData. (2026). AbbVie Research and Development (R&D) Expense — GAAP ($M) ($M), quarterly Q1 2015–Q2 2026 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/rd_gaap_exp
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.